Literature DB >> 2909797

The efficacy of acellular pertussis vaccine.

P Olin, J Storsaeter, V Romanus.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2909797

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  11 in total

1.  Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli.

Authors:  W N Burnette; J L Arciniega; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough.

Authors:  L Nencioni; M Pizza; M Bugnoli; T De Magistris; A Di Tommaso; F Giovannoni; R Manetti; I Marsili; G Matteucci; D Nucci
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

3.  Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model.

Authors:  J B Bruss; G R Siber
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

4.  Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen.

Authors:  A Kimura; K T Mountzouros; P A Schad; W Cieplak; J L Cowell
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

Review 5.  Novel therapies for the treatment of pertussis disease.

Authors:  Karen M Scanlon; Ciaran Skerry; Nicholas H Carbonetti
Journal:  Pathog Dis       Date:  2015-09-21       Impact factor: 3.166

6.  Pertussis holotoxoid formed in vitro with a genetically deactivated S1 subunit.

Authors:  T D Bartley; D W Whiteley; V L Mar; D L Burns; W N Burnette
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.

Authors:  P Askelöf; K Rodmalm; G Wrangsell; U Larsson; S B Svenson; J L Cowell; A Undén; T Bartfai
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

8.  Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin.

Authors:  R Schneerson; L Levi; J B Robbins; D M Bryla; G Schiffman; T Lagergard
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

Review 9.  Progress with a recombinant whooping cough vaccine: a review.

Authors:  W N Burnette; V L Mar; D W Whiteley; T D Bartley
Journal:  J R Soc Med       Date:  1992-05       Impact factor: 18.000

10.  Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.

Authors:  A Podda; L Nencioni; M T De Magistris; A Di Tommaso; P Bossù; S Nuti; P Pileri; S Peppoloni; M Bugnoli; P Ruggiero
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.